The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment

In conclusion, our results suggest that the anti-PD-L1&CXCR4 bispecific nanobody exerts an antitumor immune response by changing the pancreatic tumour microenvironment. Hence, the anti-PD-L1&CXCR4 bispecific nanobody is a potential candidate for pancreatic cancer treatment.PMID:38581990 | DOI:10.1016/j.intimp.2024.111944

Source: International Immunopharmacology - April 6, 2024 Category: Allergy & Immunology Authors: Yaxian Li Yuejiang Zheng Shuyi Xu Hai Hu Liyun Peng Jianwei Zhu Mingyuan Wu Source Type: research